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Critical Appraisal of the Use of Cardiac
Resynchronization Therapy Beyond Current Guidelines
Rutger J. Van Bommel, MD, Victoria Delgado, MD, Martin J. Schalij, MD, PHD,
Jeroen J. Bax, MD, PHD
Leiden, the Netherlands
Cardiac resynchronization therapy (CRT) is an effective treatment for patients with drug-refractory, chronic heart
failure. Multiple single-center and multicenter studies have shown significant reductions in left ventricular (LV)
volumes and an increase in LV systolic function. More importantly, CRT reduces mortality and morbidity during
long-term follow-up. Current guidelines consider CRT as a Class I indication for heart failure patients in New York
Heart Association (NYHA) functional class III to IV with depressed LV ejection fraction 35% and a wide QRS
complex (120 ms). However, the benefits of this therapy could possibly be extended to selected subgroups of
patients who do not fulfill these criteria. These subgroups include patients with mildly symptomatic heart failure
and patients with a narrow QRS complex (120 ms). Results from recent multicenter controlled clinical trials
including heart failure patients in NYHA functional class I to II or with a narrow QRS complex are equivocal. Al-
though expanding CRT to patients with a narrow QRS complex seems currently not likely, the benefits of CRT in
mildly symptomatic patients are more evident. Perhaps attenuation of disease progression will prove to be a
successful new treatment strategy in heart failure patients in the future. In addition, multimodality cardiac imag-
ing will allow optimizing responder rate in patients undergoing CRT according to current guidelines. (J Am Coll
Cardiol 2010;56:754–62) © 2010 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2010.04.035n
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eardiac resynchronization therapy (CRT) is an effective
reatment for patients with drug-refractory, chronic heart
ailure. Multiple single- and multicenter studies have shown
ignificant reductions in mortality and morbidity in heart
ailure patients after CRT implantation (1–5). In addition,
RT improved left ventricular (LV) performance by restor-
ng the synchronicity of the electromechanical activation,
nducing reverse remodeling, and reducing mitral regurgi-
ation (6–9). Accordingly, current guidelines consider CRT
s a Class I indication for heart failure patients in New York
eart Association (NYHA) functional class III to IV with
eft ventricular ejection fraction (LVEF) 35% and a wide
RS complex (120 ms) (10). Recently, the benefit of
RT has been explored in selected subgroups of patients
ho do not fulfill these criteria. These subgroups include
atients with mildly symptomatic heart failure and patients
ith a narrow QRS complex (120 ms). Results from
ecent multicenter controlled clinical trials including heart
ailure patients in NYHA functional class I to II or with a
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010, manuscript accepted April 6, 2010.arrow QRS complex may provide evidence to expand the
ndications of CRT (11–13). The present article reviews
hese trials and discusses the role of CRT in heart failure
atients in NYHA functional class I to II or with narrow
RS complex.
RT in Patients With Narrow QRS Complex
rolonged QRS complex duration (120 ms) indicates the
resence of cardiac dyssynchrony that can be corrected with
RT. The landmark trials that demonstrated the efficacy of
RT included heart failure patients with QRS complex
urations120 ms. Therefore, current guidelines recommend
RT only in heart failure patients with QRS complex duration
120 ms (10). However, data from the CONQUEST (Con-
estive Heart Failure and QRS Duration: Establishing
rognosis) study, including more than 3,000 heart failure
atients, demonstrated that 42% of the patients with systolic
eart failure had a QRS duration 120 ms (14). On the
asis of these data and according to current guidelines, a
ignificant percentage of heart failure patients would not be
menable for CRT. The assessment of LV mechanical
yssynchrony with different imaging modalities may iden-
ify heart failure patients who could benefit from CRT,
espite having a narrow QRS complex. Indeed, several
chocardiographic studies have demonstrated that 40% to
0% of heart failure patients with a narrow QRS complex
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August 31, 2010:754–62 CRT Beyond Current Guidelinesay also exhibit LV dyssynchrony (15). This subgroup of
atients with a narrow QRS complex, but with presence of LV
echanical dyssynchrony, may also benefit from CRT. To eluci-
ate the effects of CRT on heart failure patients with a narrow
RS complex, several single-center studies were performed,
roviding encouraging results (Table 1) (16–19). In these trials,
atients with a narrow QRS complex exhibited similar improve-
ents in clinical parameters and LVEF as patients with a wide
RS complex. Comparable observations were made in the
STEEM-CRT (Evaluation of CRT in Narrow QRS Patients
ith Mechanical Dyssynchrony From a Multicenter Study).
his study included 68 patients with NYHA functional class
II heart failure symptoms of QRS 120 ms, LVEF 35%,
nd LV mechanical dyssynchrony as defined by the standard
eviation of time to peak systolic velocity of 12 segments
Ts-SD) 28.7 ms. All patients received CRT with defibril-
ator (CRT-D) and underwent invasive rate of rise in LV
lling pressure testing for atrioventricular optimization at
mplantation. Preliminary results of this trial were presented at
he Heart Rhythm Society congress in 2008 (20). After 6
onths of follow-up, a significant reduction in NYHA func-
ional class (0.7 0.7; p 0.01) was observed, accompanied
y an improvement in quality-of-life score (23  21; p 
.01). In contrast, however, no significant changes in peak
O2 or LVEF were noted. The authors concluded from these
esults that patients with narrow QRS complex and LV
yssynchrony (using tissue Doppler imaging, Ts-SD) did not
mprove as measured by exercise performance and LV reverse
emodeling.
he RethinQ (Cardiac Resynchronization Therapy in
atients with Heart Failure and Narrow QRS) trial. The
ethinQ trial is the first randomized multicenter study in
atients with narrow QRS complex (130 ms) and in-
luded a total of 172 heart failure patients in NYHA
unctional class III with an indication for an implantable
ardioverter-defibrillator (ICD) (11). All patients showed
V mechanical dyssynchrony as assessed by echocardio-
raphic techniques (96% as assessed with tissue Doppler
enefits of CRT on Symptomatic Heart Failure Patients With a Narsults From Single-Center and Multicenter TrialsTable 1 Benefits of CRT on Symptomatic He rt Failure PatientResults From Single-Center and Multicenter Trials
Achilli et al. (16)
Patient characteristics
No. of patients 14
Age (yrs) 68 8
Male sex (%) 71
Ischemic etiology (%) 29
QRS duration (ms) 110 11
LV dyssynchrony (ms) 43 17
Effects of CRT on clinical and echocardiographic
parameters at follow-up
Reduction in NYHA functional class 1.6 0.1
Reduction in quality-of-life score NA
Improvement in 6MWD (m) 94 19
Reduction in LV end-systolic dimensions 5.8 0.2†
Improvement in LVEF (%) 9 195% confidence intervals. †Diameter (mm). ‡Volume (ml).
CRT  cardiac resynchronization therapy; LV  left ventricular; LVEF  left ventricular ejection fractionmaging and 4% as assessed with
-mode echocardiography). Af-
er implantation of a CRT device
ith cardioverter-defibrillator
apability, patients were ran-
omized to the CRT group or
he control group (no CRT).
he study failed to demonstrate
significant difference in the pri-
ary end point (increase in peak
xygen consumption 1.0 ml
er kilogram of body weight per
inute during exercise testing at
months) between the CRT
roup and the control group.
econdary end points included
hange in quality-of-life score
nd change in NYHA functional
lass at 6 months of follow-up.
hange in quality-of-life score
as similar between the CRT
roup and the control group (7
s. –8; p  0.91). However, at 6
onths of follow-up, a signifi-
antly larger proportion of pa-
ients in the CRT group improved in NYHA functional
lass by 1 point compared with patients in the control
roup (54% vs. 29%; p  0.006), although no differences in
hange in 6-min walk distance and LV volumes were noted
etween the 2 groups. When the analyses were performed
ccording to baseline QRS complex duration, those patients
ith a QRS complex between 120 and 130 ms exhibited
ignificant improvements in peak oxygen consumption and
YHA functional class, whereas those patients with a QRS
120 ms showed a significant improvement only in NYHA
unctional class (Fig. 1) (11).
Although RethinQ could not demonstrate conclusive
vidence to support CRT in narrow QRS patients by its
RS Complex:h a Narrow QRS Complex:
r et al. (17) Yu et al. (19) ESTEEM (20) RethinQ (11)
33 51 68 87
3 11 63 11 58 14 60 12
85 78 68 71
70 49 60 54
0 8 103 13 102 10 107 12
2 32 36 14 45 21 81 39
9 0.6 0.7 0.4 0.7 0.7 54% improved
3 16 8 19 23 21 8 (1–10)*
9 107 46 88 NA 26 (01–46)*
9 34‡ 17 19‡ 5 40‡ 19 (121–34)*‡
8 8 7 6 0.8 8.2 1.2 (0.41–4.4)*
Abbreviations
and Acronyms
CI  confidence interval
CRT  cardiac
resynchronization therapy
CRT-D  cardiac
resynchronization therapy
with defibrillator
ECG  electrocardiography
HR  hazard ratio
ICD  implantable
cardioverter-defibrillator
LV  left ventricular
LVEF  left ventricular
ejection fraction
LVESV  left ventricular
end-systolic volume
LVESVi  left ventricular
end-systolic volume index
NYHA  New York Heart
Association
RBBB  right bundle-
branch blockrow Qs Wit
Bleeke
6
11
10
0.
1
8
3; 6MWD  6-min walk distance; NYHA  New York Heart Association.
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CRT Beyond Current Guidelines August 31, 2010:754–62rimary end point of peak myocardial oxygen consumption,
here was a significant improvement in NYHA functional
lass in the CRT group as compared with the control group.
he limited benefits of CRT in patients with narrow QRS
omplex may be explained by the presence of short LV
lectrical activation delays as recently demonstrated (21,22).
he time delay between onset of the QRS complex to the
atest activated area of the left ventricle may indicate the
mount of global LV dyssynchrony amenable to be cor-
ected through CRT. In patients with left bundle-branch
lock morphology, the LV activation delays are usually
onger than those observed in patients with narrow QRS
omplex or right bundle-branch block (RBBB). Indeed,
atients with QRS duration 150 ms and left bundle-
ranch block morphology showed the highest response rates
n recent multicenter trials (12,13). In contrast, patients
ith short LV activation delays or with the latest activated
reas located far away from the vein targeted by the LV
acing lead (patients with RBBB or anterior myocardial
car) may show less clinical and echocardiographic improve-
ent at mid- or long-term follow-up after CRT (23,24). In
his regard, accurate identification of the latest mechanically
ctivated areas to guide the LV lead positioning may help to
mprove the response rates to CRT. The use of noninvasive
maging techniques to evaluate either the electrical or
echanical substrate of LV dyssynchrony will help to
dentify the patients with narrow QRS complex or RBBB
ho will benefit from CRT.
It should be emphasized that the current 2 trials (ESTEEM-
RT and RethinQ) included few patients, had limited
ollow-up (up to 6 months), and did not focus on re-
ospitalization and long-term survival. Currently, there is a
arge prospective randomized trial ongoing that will focus
n exactly these issues. The EchoCRT (Echocardiography
uided Cardiac Resynchronization Therapy) trial will in-
lude more than 1,000 patients, carefully selected by novel
dvanced echo techniques, evaluated by a single core labo-
atory before entrance in the study (25). Patients are
Figure 1 Effects of CRT in Patients With Narrow QRS Complex
At 6 months of follow-up, those patients with a QRS between 120 and 130 ms sh
Association (NYHA) functional class (B) as compared with controls. However, patie
functional class. Adapted, with permission, from Beshai et al. (11). CRT  cardiacandomized to CRT or no CRT, and patients in both study Lrms will receive an ICD. The primary end point is all-cause
ortality or hospitalization for cardiovascular events during
ong-term follow-up.
There are several other ongoing studies evaluating the
ffects of CRT in heart failure patients with narrow QRS
omplex. The CRT-Narrow (Cardiac Resynchronization
herapy–Narrow-dp/dt) is a nonrandomized study that
valuates acute and midterm effects of CRT on LV function
y invasive measures of LV performance and LV reverse
emodeling (26). Finally, the EARTH (Evaluation of Re-
ynchronization Therapy for Heart Failure) trial (27) will
nvestigate the impact of LV mechanical dyssynchrony on
linical outcome of symptomatic heart failure patients with
narrow QRS complex (130 ms). The results of these
rials may determine the subsequent dissemination of CRT
n this specific group of patients.
RT in Mild Heart Failure
o date, the vast majority of patients in the large CRT trials
ere in NYHA functional class III and IV. The 2 largest
rials that showed a survival benefit for CRT over optimal
edical therapy alone included patients only in NYHA
unctional class III and IV. As a result, current guidelines
onsider CRT as a Class I indication only for heart failure
atients in NYHA functional class III to IV (10).
Much less is known about the effects of CRT in patients
ith mild symptoms of heart failure. Some studies have
ypothesized that CRT in mildly symptomatic heart failure
atients might prevent heart failure worsening. In the
IRACLE ICD II (Multicenter InSync Randomized
linical Evaluation II) trial, 186 patients in NYHA func-
ional class II with LVEF35%, a QRS complex130 ms,
nd a Class I indication for an ICD were implanted with a
RT-D device and then randomized to receive biventricu-
ar pacing (“CRT-ON,” n  85) or no biventricular pacing
“CRT-OFF,” n  101) (28). At 6 months of follow-up,
atients in the CRT-ON group had a greater reduction in
e RethinQ Trial
a significant improvement in peak oxygen consumption (A) and New York Heart
ith a QRS duration 120 ms showed only a significant improvement in NYHA
chronization therapy.in th
owed
nts w
resynV diastolic and systolic volumes (p  0.04 and p  0.01,
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August 31, 2010:754–62 CRT Beyond Current Guidelinesespectively). In addition, CRT-ON recipients showed
tatistically significant improvement in NYHA functional
lass and clinical composite (29) response (p  0.05 and
 0.01, respectively). There were no significant differ-
nces in improvement in peak oxygen consumption, 6-min
alking distance, or quality-of-life scores (28). Similar
esults were reported by the CONTAK-CD (CONTAK-
ardiac Defibrillator) trial, with significant reductions in
V dimensions (5).
The results of CONTAK-CD and MIRACLE ICD
I, together with the observation that LV reverse remod-
ling was a better predictor of long-term survival than
linical improvement (30), led to the use of LV reverse
emodeling as an end point in clinical randomized CRT
rials. Because patients with mild heart failure symptoms
ay also exhibit depressed LV function and wide QRS
omplex, 2 large clinical trials were conducted to inves-
igate whether CRT could prevent or attenuate disease
rogression and induce LV reverse remodeling in this
roup (Table 2) (31,32).
he REVERSE (Resynchronization Reverses Remodeling
n Systolic Left Ventricular Dysfunction) trial. REVERSE
as a randomized, double-blind trial investigating the
ffects of CRT in patients with asymptomatic and mildly
ymptomatic heart failure and a prolonged QRS interval
12). The study hypothesized that CRT might delay
isease progression in heart failure patients with less
evere symptoms by inducing LV reverse remodeling.
ligible patients were in NYHA functional class I or II
or at least 3 months before enrollment. Patients were
equired to be in sinus rhythm with a QRS duration
120 ms, to have LVEF 40%, and to have an LV
nd-diastolic diameter 55 mm (Table 2).
The primary end point of the study was the heart failure
linical composite response (29). The main secondary end
oint was the absolute change in left ventricular end-systolic
olume index (LVESVi) between baseline and 12 months of
ollow-up. A total of 610 patients were included between
Comparison of the MADIT-CRT and REVERSE TrTable 2 Comparison of the MADIT-CRT and
REVERSE
Inclusion criteria
LVEF (%) 4
QRS duration (ms) 12
NHYA functional class I/I
Study design
Randomization (CRT vs. control) 2:1
ICD Yes/
Primary end point HF C
Results
No. of patients 61
NHYA functional class II 503 (8
Ischemic heart disease 333 (5
Outcome summary No less worsening in C
vs. 21% in CRT-OFF
CCS  clinical composite score; HF  heart failure; ICD  implantableptember 2004 and September 2006. After enrollment,19 were randomized to CRT-ON and 191 were random-
zed to CRT-OFF. In the CRT-ON group, 16% worsened
n their heart failure clinical composite response at 1 year, as
ompared with 21% of patients in the CRT-OFF group
p  0.10) (Fig. 2). The LVESVi decreased significantly in
he CRT-ON group (18.4  29.5 ml/m2), whereas no
hange in LVESVi (1.3  23.4 ml/m2) was observed in
he CRT-OFF group (p  0.0001). This decrease in
VESVi was even more evident in patients with a QRS
uration 152 ms as compared with patients with a QRS
uration152 ms. Also, a significant increase in LVEF was
bserved in the CRT-ON group (3.8%), whereas no
ignificant change (0.6%) was noted in the CRT-OFF
roup (p  0.0001). Finally, CRT reduced the risk of heart
ailure hospitalization (hazard ratio [HR]: 0.46; p  0.03).
lthough REVERSE failed to show a difference in the
rimary end point, the results indicate that CRT can reverse
V remodeling and reduce the risk for heart failure hospi-
Figure 2 The Heart Failure Clinical Composite Score
Response (Primary End Point) in the REVERSE Trial
Comparison of proportion of worsened patients at 12 months (p  0.10).
Adapted, with permission, from Linde et al. (12). CRT  cardiac resynchroniza-
tion therapy.
RSE Trials
) MADIT-CRT (13,32)
30
130
I/II
3:2
Yes
All-cause mortality or HF event
1,820
1,555 (85%)
999 (55%)
% in CRT-ON
.10)
Significant reduction in all-cause mortality
or HF event (HR: 0.66, p  0.001)
verter-defibrillator; other abbreviations as in Table 1.ialsREVE
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CRT Beyond Current Guidelines August 31, 2010:754–62alization in mildly symptomatic heart failure patients
NYHA functional class I and II), thereby delaying disease
rogression in these patients.
Recently, Daubert et al. (33) reported the results from
he 24-month follow-up of the European cohort of
EVERSE. In this subgroup, the 262 European patients
n REVERSE were followed for 24 months (in contrast
o the 12-month follow-up in the main trial). Over this
4-month follow-up period, CRT resulted in less clinical
orsening and an improvement in LV function. There
as a significant reduction in the clinical composite end
oint in the CRT group (19% worsened in the CRT-ON
roup as compared with 34% of patients in the CRT-
FF group; p  0.01). In addition, LVESVi decreased
ignificantly in the CRT-ON group (decrease of 27.5 
1.8 ml/m2 in the CRT-ON group vs. 2.7  25.8 ml/m2
n the CRT-OFF group; p  0.0001). Finally, a signif-
cant reduction in time to first heart failure hospitali-
ation or death was observed in the CRT-ON group
HR: 0.38; p  0.003) (Fig. 3). These results provide
urther evidence that CRT might be useful in delaying
eart failure worsening.
he MADIT-CRT (Multicenter Automatic Defibrillator
mplantationTrial withCardiac ResynchronizationTherapy).
he MADIT-CRT trial enrolled 1,820 patients between
ecember 2004 and April 2008 (13). It was designed to
etermine whether CRT-D would reduce the risk of mor-
ality and heart failure events as compared with ICD only in
ubjects with NYHA functional class I to II heart failure,
VEF 30%, and QRS duration 130 ms. Other end
oints included changes in left ventricular end-systolic
olume (LVESV) at 1 year of follow-up, changes in LV
nd-diastolic volume at 1-year follow-up, and subject-
pecific rates of multiple heart failure events.
During follow-up, 187 of 1,089 patients (17.2%) in the
RT-D group reached the primary end point, as com-
ared with 185 of 731 patients (25.3%) in the ICD-only
roup (HR: 0.66; 95% confidence interval [CI]: 0.52 to
.84; p  0.001) (Fig. 4). This superiority of CRT-D
ver ICD only was driven by a 41% reduction in the risk
f heart failure events. There was no difference in
ortality between the groups, with a 3% annual mortality
n both groups. Interestingly, the beneficial effect of CRT
n the primary end point was greater in patients with a
RS duration 150 ms than in patients with a QRS
uration 150 ms (HR: 0.48, 95% CI: 0.37 to 0.64 vs.
R: 1.06, 95% CI: 0.74 to 1.52; p  0.001 for interac-
ion). In addition to these findings, a reduction of 52 ml
n LV end-diastolic volume was observed at 1 year of
ollow-up in the CRT-D group, compared with a 15-ml
eduction in the ICD-only group, p  0.001 (Fig. 5).
inally, a reduction of 57 ml in LVESV was observed in
he CRT-D group, as compared with 18 ml in the
CD-only group, p  0.001 (Fig. 5). The results of
ADIT-CRT provide evidence that preventive therapyFigure 3 Long-Term Follow-Up in the European REVERSE Patients
(A) Time to first hospitalization for heart failure (HF) or death from any cause;
(B) time to first hospitalization for HF; and (C) time to death from any cause.
p values are from the log-rank test. Adapted, with permission, from Daubert et
al. (33). CRT  cardiac resynchronization therapy; HR  hazard ratio.
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August 31, 2010:754–62 CRT Beyond Current Guidelinesith CRT-D in heart failure patients with minimal heart
ailure symptoms, but a wide QRS complex and a low
VEF, decreases the risk of heart failure events.
Currently, there is another large trial ongoing in patients
ith mild heart failure symptoms. RAFT (Resynchroniza-
ion/Defibrillation for Ambulatory Heart Failure Trial) will
nclude 1,800 subjects in NYHA functional class II, LVEF
30%, and QRS duration 120 ms (34). Patients will then
e randomized to receive either ICD or CRT-D in a 1:1
ashion. The primary end point is a composite of total
ortality and heart failure hospitalization during long-term
ollow-up. The results of this large randomized trial are
agerly awaited.
uture Perspective
he future of CRT might be heading toward 2 separate
irections: 1) to improve the responder rate in patients
ndergoing CRT according to current guidelines; and 2) to
xpand treatment to patient groups that might also benefit
rom CRT.
mproving response rate. In order to optimize CRT re-
ponse rate, numerous studies have focused on identifying
ossible responders before implantation by means of echocar-
iography. A recent subanalysis of the PROSPECT (Predic-
ors of Response to Cardiac Resynchronization Therapy) trial
evealed that patients with more extensive LV dyssynchrony
ad more pronounced reduction in LVESV at 6 months of
ollow-up (35). This finding emphasizes the relation between
re-implantation LV dyssynchrony and outcome after CRT.
onversely, it remains currently unclear which measure of
yssynchrony should be used and which cut-off value for
yssynchrony should be considered to select patients for CRT
mplantation. In addition to the use of echocardiographic
Figure 4 Long-Term Follow-Up in MADIT-CRT
There was a significant difference in survival free of heart failure between the
group that received cardiac resynchronization therapy (CRT) plus an implant-
able cardioverter-defibrillator (ICD) and the group that received an ICD only
(unadjusted p  0.001 by the log-rank test). Adapted, with permission, from
Moss et al. (13).easurements to predict response to CRT, a more recent studydentified several electrocardiography (ECG) patterns as po-
ential determinants of CRT response (36). In particular,
onger LV activation times, lower QRS scar score, and evi-
ence of wavefront fusion after CRT initiation, as measured
rom the surface ECG, were potent markers of significant LV
everse remodeling at 6 months of follow-up. Using an
lgorithm based on these specific ECG parameters may also
urther optimize patient selection for CRT.
Furthermore, the extent and location of myocardial scar
nd the presence of a suitable venous anatomy to place the
V pacing lead at the latest activated area of the left
entricle are crucial determinants of a favorable response to
RT (37). Therefore, an integrated approach evaluating LV
yssynchrony, total myocardial scar burden, and cardiac
enous anatomy may refine the selection of potential re-
ponders to CRT. Currently, magnetic resonance imaging,
uclear imaging, and multidetector-row computed tomog-
aphy constitute valuable imaging techniques to evaluate all
hese parameters (37).
Finally, the LV pacing lead location may be of impor-
ance. Several studies have indicated that positioning the
V lead outside the region of latest activation may reduce
he response rate after CRT (38,39). In addition, (transmu-
al) scar at the location of the LV pacing lead may also result
n nonresponse after CRT, making scar assessment of
ignificant importance in ischemic heart failure patients
efore device implantation (40). Taking all this into con-
ideration, an integrated approach on these factors may
mprove response to CRT, rather than relying on any single
easure (Fig. 6) (41).
After CRT device implantation, cardiac imaging plays a
entral role in the evaluation of response to CRT. Among
everal parameters proposed to define response to CRT,
eduction in LVESV 15% has demonstrated to be inde-
endently related to improved long-term clinical outcome
Figure 5
Changes in Mean Echocardiographic
LV Volumes and LVEF Between Baseline
and 1-Year Follow-Up in the MADIT-CRT Trial
There were significant differences in changes in left ventricular (LV) volumes
and left ventricular ejection fraction (LVEF) between the 746 patients who
received CRT–ICD and the 620 patients who received an ICD only. Adapted,
with permission, from Moss et al. (13). LVEDV  left ventricular end-diastolic
volume; LVESV  left ventricular end-systolic volume; other abbreviations as in
Figure 4.
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CRT Beyond Current Guidelines August 31, 2010:754–6230,42). Accordingly, current single-center and multicenter
rials include this end point as the definition of response to
RT. Echocardiography is the most frequently used imag-
ng technique to evaluate changes in LV volumes. However,
he use of 3-dimensional imaging modalities such as real-
ime 3-dimensional echocardiography or magnetic reso-
ance imaging may provide a more accurate estimation of
V volumes and ejection fraction (43). Particularly, the
evelopment of CRT devices compatible with magnetic
esonance systems is important, so that LV volumes can be
ssessed with this modality after CRT implantation (44).
inally, a multidisciplinary evaluation of heart failure pa-
ients treated with CRT including further adjustments of
he device settings and medical treatment may improve the
esponse rate to CRT as recently demonstrated by Mullens
t al. (45).
xpanding treatment to other patient groups, outside
urrent guidelines. Perhaps the most important issue
aised by the results of these recent large trials is whether
he current indications for CRT should be expanded. The
erformance of current inclusion criteria for CRT implan-
ation may be suboptimal because they may exclude some
roups of patients who may benefit from CRT. Indeed,
efinitions of heart failure are imprecise, and the majority
ncludes typical symptoms and objective evidence of LV
ysfunction. Currently, only heart failure patients in NYHA
unctional class III to IV and with LVEF 35% are
onsidered candidates for CRT implantation. However,
hese inclusion criteria exclude patients in NYHA func-
ional class I to II who may benefit from CRT by preventing
rogression of the disease, as recently observed in the
ADIT-CRT and REVERSE trials (12,13).
Both trials have demonstrated the effect of CRT to
mprove LV function and prevent heart failure progression
n mildly symptomatic heart failure patients (12,13), and
Figure 6 Algorithm to Help Determine Whether the Patient
Has a High or Low Likelihood of Response to CRT
Integrating information on various factors for prediction of response to CRT
may improve response rates. Important issues are LV dyssynchrony, scar tis-
sue in the region where the LV pacing lead is positioned, the total extent of
scar in the LV, and whether the LV lead is positioned in the site of latest
mechanical activation. Adapted, with permission, from Bax et al. (41). NYHA 
New York Heart Association; other abbreviations as in Figures 4 and 5.xpansion of guidelines for CRT selection may be consid-red. Perhaps attenuation of disease progression, rather than
eversing severe heart failure, will prove to be a successful
ew treatment strategy in heart failure patients in the future,
lthough more data on survival benefit in these patients may
e needed before definitive conclusions can be drawn.
Conversely, the results from ESTEEM-CRT and
ethinQ (11,20) make the expansion of CRT to heart
ailure patients with a narrow QRS complex currently
nlikely. However, the results of the ongoing EchoCRT
rial will determine whether CRT is an effective treatment
ption in this specific group of patients (25). The last
entioned trial will be the first to use the newly proposed
peckle tracking echocardiographic technique for evaluation
f LV mechanical dyssynchrony. This novel methodology
ermits the assessment of active myocardial deformation,
rovides accurate information on LV dyssynchrony, and
ermits identification of the area of latest mechanical
ctivation. This more robust method of dyssynchrony as-
essment may improve selection of suitable candidates for
RT.
Finally, there are a few other cardiac conditions for which
RT indication is still controversial. It has been suggested
hat atrial fibrillation may convey a lower response rate to
RT (46,47). A recent meta-analysis including 1,146 heart
ailure patients compared the clinical and echocardiographic
esponse to CRT in patients with sinus rhythm (n  797)
r atrial fibrillation (n  367) (48). Both patient groups
howed significant improvement in NYHA functional class,
VEF, and long-term survival after CRT; the need for
trioventricular junction ablation in atrial fibrillation is still
ot entirely clear (46,47,49).
Other clinical conditions, such as upgrading from right
entricular pacing, right-sided heart failure, and congenital
eart disease, have also demonstrated clinical benefit from
RT (50–52). Patients with drug-refractory heart failure
ut preserved LVEF (35%) and impaired LV filling may
lso benefit from CRT (53). However, more data are
eeded in these subpopulations.
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